uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.1890 | Q34 | What are the names of the genes that are targeted by the drug Torsemide in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Torsemide targets the gene solute carrier family 12 member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%torsemide%" OR LOWER(tradeNames_list) LIKE "%torsemide%" OR LOWER(syns_list) LIKE "%torsemide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149088', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1149096', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.18 | Q34 | What are the names of the genes that are targeted by the drug Cyclobenzaprine Hydrochloride in the treatment of cerebral palsy? | In the context of cerebral palsy, the drug Cyclobenzaprine Hydrochloride targets the gene 5-hydroxytryptamine receptor 2C and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cerebral palsy%" OR LOWER(efo_term) LIKE "%cerebral palsy%") AND (LOWER(drugName) LIKE "%cyclobenzaprine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cyclobenzaprine hydrochloride%" OR LOWER(syns_list) LIKE "%cyclobenzaprine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_151280', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151298', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151304', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151310', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151322', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151328', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151334', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151346', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151352', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151358', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151364', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151376', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151382', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151388', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151394', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151400', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151406', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151412', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151418', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151424', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151430', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151436', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151340', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151292', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151268', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151256', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151250', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151370', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151316', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151286', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151274', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151262', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.129 | Q34 | What are the names of the genes that are targeted by the drug Levomilnacipran in the treatment of unipolar depression? | In the context of unipolar depression, the drug Levomilnacipran targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%levomilnacipran%" OR LOWER(tradeNames_list) LIKE "%levomilnacipran%" OR LOWER(syns_list) LIKE "%levomilnacipran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206892', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206904', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206908', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206912', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206920', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206924', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206928', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206936', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206940', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206944', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206948', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206956', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206960', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206964', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206968', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206971', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206974', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206977', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206980', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206983', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206986', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206992', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206995', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206998', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207001', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207004', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207010', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207013', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207016', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207019', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207022', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207025', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207028', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207031', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207034', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_207037', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206989', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206932', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206900', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206884', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206876', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206872', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207007', 'drugName': 'Levomilnacipran', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran', 'F 2695', 'F-2695', 'F2695', 'LevomilnacipranMilnacipran, (1s,2r)-']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206952', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206916', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206896', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206888', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206880', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1357 | Q34 | What are the names of the genes that are targeted by the drug Acalabrutinib in the treatment of chronic lymphocytic leukemia? | In the context of chronic lymphocytic leukemia, the drug Acalabrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic lymphocytic leukemia%" OR LOWER(efo_term) LIKE "%chronic lymphocytic leukemia%") AND (LOWER(drugName) LIKE "%acalabrutinib%" OR LOWER(tradeNames_list) LIKE "%acalabrutinib%" OR LOWER(syns_list) LIKE "%acalabrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_994091', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994160', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994183', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994206', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994252', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994275', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994298', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994344', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994367', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994390', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994413', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994459', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994482', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994505', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994528', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994551', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994574', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994597', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994620', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994643', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994666', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994712', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994735', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994758', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994781', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994804', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994850', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994873', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994896', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994919', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994942', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994965', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994988', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024984', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024986', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024988', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024990', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024992', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024994', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024996', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024998', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025000', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025002', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025004', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025006', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025008', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025010', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025012', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025014', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025016', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025018', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025022', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025024', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025026', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025028', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025030', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025032', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025036', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025038', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025040', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025042', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025044', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025046', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025048', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025050', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025052', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025054', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025056', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025058', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025060', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025062', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025064', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025066', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025068', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025070', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025072', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025020', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994689', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994321', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994137', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994045', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_993999', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_993976', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025034', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994827', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994436', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994229', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994114', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994068', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994022', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1290 | Q34 | What are the names of the genes that are targeted by the drug Alectinib Hydrochloride in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Alectinib Hydrochloride targets the gene ret proto-oncogene, ALK receptor tyrosine kinase and EMAP like 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%alectinib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%alectinib hydrochloride%" OR LOWER(syns_list) LIKE "%alectinib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_945566', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945569', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945570', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945571', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945573', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945574', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945575', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945576', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945568', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945564', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945562', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945561', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945572', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945567', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945565', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945563', 'drugName': 'Alectinib Hydrochloride', 'tradeNames_list': "['Alecensa']", 'syns_list': "['Alectinib hydrochloride']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1949 | Q34 | What are the names of the genes that are targeted by the drug Sodium Oxybate in the treatment of narcolepsy-cataplexy syndrome? | In the context of narcolepsy-cataplexy syndrome, the drug Sodium Oxybate targets the gene gamma-aminobutyric acid type B receptor subunit 1 and gamma-aminobutyric acid type B receptor subunit 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%narcolepsy-cataplexy syndrome%" OR LOWER(efo_term) LIKE "%narcolepsy-cataplexy syndrome%") AND (LOWER(drugName) LIKE "%sodium oxybate%" OR LOWER(tradeNames_list) LIKE "%sodium oxybate%" OR LOWER(syns_list) LIKE "%sodium oxybate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192765', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192801', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192813', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192825', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192849', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192861', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192873', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192897', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192909', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192921', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192933', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192957', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192969', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192981', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192993', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193005', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193017', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193029', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193041', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193053', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193065', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193089', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193101', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193077', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192885', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192789', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192717', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192705', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192741', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192945', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192837', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192777', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192753', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192729', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.934 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of pain? | In the context of pain, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840159', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841666', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841665', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840001', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840080', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841660', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840481', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840322', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841113', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840712', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841428', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840870', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840317', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839770', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839843', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841739', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840954', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839848', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839849', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841507', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840244', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840560', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841034', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840164', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841192', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839928', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840718', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841581', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840243', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841429', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839769', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841587', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841586', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840401', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840955', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841423', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840007', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840006', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840323', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841502', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840402', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840085', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841745', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840639', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840875', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840475', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840480', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840791', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840086', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840796', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841508', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840559', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841028', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839764', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841107', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839927', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840633', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841349', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840165', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841191', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841186', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841344', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840717', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841271', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841270', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841744', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841350', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841112', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841033', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840554', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839922', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840876', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840396', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840638', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841265', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840797', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840949', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840238', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840925', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neck Pain', 'efo_term': 'Neck pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839740', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neck Pain', 'efo_term': 'Neck pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839895', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840053', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840369', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841003', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841004', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neck Pain', 'efo_term': 'Neck pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840371', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840372', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neck Pain', 'efo_term': 'Neck pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840055', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840056', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neck Pain', 'efo_term': 'Neck pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840448', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841001', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839816', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839897', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840450', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840451', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neck Pain', 'efo_term': 'Neck pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839898', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neck Pain', 'efo_term': 'Neck pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840527', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840132', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840529', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840530', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neck Pain', 'efo_term': 'Neck pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.987 | Q34 | What are the names of the genes that are targeted by the drug Palbociclib in the treatment of cancer? | In the context of cancer, the drug Palbociclib targets the gene cyclin dependent kinase 4, cyclin dependent kinase 6 and cyclin D1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%palbociclib%" OR LOWER(tradeNames_list) LIKE "%palbociclib%" OR LOWER(syns_list) LIKE "%palbociclib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_851620', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851972', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852635', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852060', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851400', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852151', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851359', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851532', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852371', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851796', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852679', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852852', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852063', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853204', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853119', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853248', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851488', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853339', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851403', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853383', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851708', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852195', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852283', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851755', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852456', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851975', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852500', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852808', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851576', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852720', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851447', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852896', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851884', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852940', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852943', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853295', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851931', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853163', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853160', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853292', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853207', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853251', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851664', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853468', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851491', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853336', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852148', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853427', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853380', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853424', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851711', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852104', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852239', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852236', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852327', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851752', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852324', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852588', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852016', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852415', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852412', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852547', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851799', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852544', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852503', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853072', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852632', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852676', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851840', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852767', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851579', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852764', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852723', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853031', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852811', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852855', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851887', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853028', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852899', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852987', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852984', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853471', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851928', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852107', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851623', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853515', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853512', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853075', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852591', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852368', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852280', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852192', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852019', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851535', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852459', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851843', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_853116', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851667', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851444', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851356', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1945 | Q34 | What are the names of the genes that are targeted by the drug Sapropterin Dihydrochloride in the treatment of phenylketonuria? | In the context of phenylketonuria, the drug Sapropterin Dihydrochloride targets the gene phenylalanine hydroxylase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%phenylketonuria%" OR LOWER(efo_term) LIKE "%phenylketonuria%") AND (LOWER(drugName) LIKE "%sapropterin dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%sapropterin dihydrochloride%" OR LOWER(syns_list) LIKE "%sapropterin dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192284', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192305', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192306', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192316', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192327', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192328', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192338', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192349', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192350', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192360', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192361', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192372', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192382', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192383', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192393', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192394', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192404', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192405', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192415', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192416', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192426', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192437', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192438', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192448', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192449', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192459', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192470', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192471', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192481', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192482', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192492', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192493', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192503', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192504', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192514', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192515', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192525', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192526', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192536', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192537', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192547', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192548', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192558', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192559', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192569', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192570', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192580', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192581', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192591', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192592', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192602', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192613', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192614', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192624', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192625', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192635', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192636', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192647', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192657', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192658', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192603', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192427', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192339', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192295', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192273', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192262', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192261', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192646', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192460', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192371', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192317', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192294', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192283', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192272', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'phenylketonuria', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.192 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of synovitis? | In the context of synovitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%synovitis%" OR LOWER(efo_term) LIKE "%synovitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218091', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218490', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218507', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218698', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218906', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218923', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219114', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219322', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219339', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219530', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219547', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219755', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219946', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219963', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220154', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220171', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220362', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220379', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220570', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220587', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220778', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220795', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219131', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218299', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217883', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217675', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217658', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219738', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218715', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218282', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218074', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217866', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Synovitis', 'efo_term': 'synovitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1147 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of acute myeloid leukemia? | Trametinib has not been approved by the FDA as a treatment for acute myeloid leukemia, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute myeloid leukemia%" OR LOWER(efo_term) LIKE "%acute myeloid leukemia%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928695', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928815', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928855', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928895', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928975', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929015', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929055', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929135', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929175', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929215', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929255', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929335', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929375', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929415', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929455', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929495', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929535', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929575', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929615', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929655', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929695', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929775', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929815', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929855', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929895', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929935', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930015', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930055', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930095', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930135', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930175', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930215', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930255', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930295', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930335', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930375', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930415', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930455', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930495', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930535', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930575', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930615', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930655', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930695', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930735', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930775', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930815', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930855', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930895', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930935', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930975', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931055', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931095', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931135', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931175', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931215', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931255', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931335', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931375', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931415', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931455', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931495', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931535', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931575', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931615', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931655', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931695', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931735', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931775', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931815', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931855', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931895', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931935', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931975', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932015', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932055', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932095', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932135', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932175', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932215', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932255', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932295', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932335', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932375', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932415', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932455', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931015', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929735', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929095', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928775', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928615', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928535', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928495', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931295', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929975', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929295', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928935', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928735', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928655', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928575', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.999 | Q34 | What are the names of the genes that are targeted by the drug Umeclidinium Bromide in the treatment of emphysema? | In the context of emphysema, the drug Umeclidinium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%emphysema%" OR LOWER(efo_term) LIKE "%emphysema%") AND (LOWER(drugName) LIKE "%umeclidinium bromide%" OR LOWER(tradeNames_list) LIKE "%umeclidinium bromide%" OR LOWER(syns_list) LIKE "%umeclidinium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857416', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857431', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857436', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857426', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857396', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857391', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857406', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857421', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857411', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857401', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1936 | Q34 | What are the names of the genes that are targeted by the drug Belzutifan in the treatment of neoplasm? | In the context of neoplasm, the drug Belzutifan targets the gene endothelial PAS domain protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%belzutifan%" OR LOWER(tradeNames_list) LIKE "%belzutifan%" OR LOWER(syns_list) LIKE "%belzutifan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192111', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192119', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1642 | Q34 | What are the names of the genes that are targeted by the drug Tadalafil in the treatment of benign prostatic hyperplasia? | In the context of benign prostatic hyperplasia, the drug Tadalafil targets the gene phosphodiesterase 5A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%benign prostatic hyperplasia%" OR LOWER(efo_term) LIKE "%benign prostatic hyperplasia%") AND (LOWER(drugName) LIKE "%tadalafil%" OR LOWER(tradeNames_list) LIKE "%tadalafil%" OR LOWER(syns_list) LIKE "%tadalafil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094100', 'drugName': 'Tadalafil', 'tradeNames_list': "['Adcirca', 'Cialis', 'Tadliq']", 'syns_list': "['IC-351', 'IC351', 'LY-450190', 'LY450190', 'NSC-750236', 'NSC-759172Tadalafil', 'Tadalafil mylan', 'Trans-tadalafil']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Hyperplasia', 'efo_term': 'benign prostatic hyperplasia', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.611 | Q34 | What are the names of the genes that are targeted by the drug Cabozantinib S-Malate in the treatment of clear cell renal carcinoma? | In the context of clear cell renal carcinoma, the drug Cabozantinib S-Malate targets the gene kinase insert domain receptor and MET proto-oncogene, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%clear cell renal carcinoma%" OR LOWER(efo_term) LIKE "%clear cell renal carcinoma%") AND (LOWER(drugName) LIKE "%cabozantinib s-malate%" OR LOWER(tradeNames_list) LIKE "%cabozantinib s-malate%" OR LOWER(syns_list) LIKE "%cabozantinib s-malate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_669671', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669740', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669763', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669786', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669832', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669855', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669878', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669924', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669947', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669970', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669993', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670039', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670062', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670085', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670108', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670131', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670154', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670177', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670200', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670223', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670246', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670292', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670315', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670338', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670361', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670384', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670430', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670453', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670476', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670499', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670522', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670545', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670568', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670591', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670614', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670637', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670660', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670683', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670706', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670729', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670752', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670775', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670798', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670821', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670844', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670867', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670890', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670913', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670936', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670959', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670982', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671028', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671051', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671074', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671097', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671120', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671143', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671189', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671212', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671235', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671258', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671281', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671304', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671327', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671350', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671373', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671396', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671419', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671442', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671465', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671488', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671511', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671534', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671557', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671580', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671603', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671626', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671649', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671672', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671695', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671718', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671741', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671764', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671787', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671810', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671833', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671005', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_670269', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669901', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669717', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669625', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669579', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669556', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_671166', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_670407', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670016', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669809', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669694', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669648', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669602', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.182 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of hemolytic anemia? | In the context of hemolytic anemia, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemolytic anemia%" OR LOWER(efo_term) LIKE "%hemolytic anemia%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218688', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219312', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219520', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219728', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220144', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220352', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220560', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220768', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219104', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218272', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217856', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217648', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219936', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218896', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218480', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218064', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.303 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of diabetic retinopathy? | In the context of diabetic retinopathy, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetic retinopathy%" OR LOWER(efo_term) LIKE "%diabetic retinopathy%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227758', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228613', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228898', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229183', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229753', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230038', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230323', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230893', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231178', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231463', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231748', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232318', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230608', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228328', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227188', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226618', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226333', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232033', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229468', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228043', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227473', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226903', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetic Retinopathy', 'efo_term': 'diabetic retinopathy', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.500 | Q34 | What are the names of the genes that are targeted by the drug Methylphenidate in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Methylphenidate targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%methylphenidate%" OR LOWER(tradeNames_list) LIKE "%methylphenidate%" OR LOWER(syns_list) LIKE "%methylphenidate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_435220', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435253', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435264', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435275', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435297', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435308', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435319', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435341', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435352', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435363', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435374', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435396', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435407', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435418', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435429', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435440', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435451', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435462', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435473', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435484', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435495', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435517', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435528', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435539', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435550', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435561', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435583', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435594', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435605', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435616', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435627', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435638', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435649', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435660', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435671', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435682', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435693', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435704', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435715', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435726', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435737', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435748', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435759', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435770', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435781', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435792', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435803', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435814', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435825', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435836', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435847', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435869', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435880', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435891', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435902', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435913', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435924', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435946', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435957', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435968', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435979', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435990', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436001', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436012', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436023', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436034', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436045', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436056', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436067', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436078', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436089', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436100', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436111', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436122', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436133', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436144', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436155', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436166', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436177', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436188', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436199', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436210', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436221', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436232', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436243', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_436254', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435858', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435506', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435330', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435242', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435198', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435176', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435165', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435935', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435572', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435385', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435286', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435231', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435209', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_435187', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_list': "['Adhansia xr', 'Aptensio xr', 'Concerta', 'Delmosart', 'Equasym', 'Equasym xlJornay pm', 'Matoride xl', 'Medikinet', 'Medikinet xl', 'Metadate cdMetadate er', 'Methylin', 'Methylin er', 'Methylphenidate hydrochlorideQuillichew er', 'Quillivant xr', 'Relexxii', 'Ritalin', 'Ritalin laRitalin sr', 'Ritalin-sr', 'Tranquilyn', 'Xenidate xl']", 'syns_list': "['Aptensio', 'Aptensio xr', 'Foquest', 'Metadate', 'Methylphenidate HClMethylphenidate hcl', 'Methylphenidate hydrochlorideMethylphenidate hydrochloride cii', 'NSC-169868', 'Oros mph', 'QuillichewQuillivant', 'SPD-544', 'SPD544']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1681 | Q34 | What are the names of the genes that are targeted by the drug Canagliflozin in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Canagliflozin targets the gene solute carrier family 5 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%canagliflozin%" OR LOWER(tradeNames_list) LIKE "%canagliflozin%" OR LOWER(syns_list) LIKE "%canagliflozin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095948', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095975', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095984', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095993', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096011', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096020', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096029', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096047', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096056', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096065', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096074', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096092', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096101', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096110', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096119', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096128', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096137', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096146', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096155', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096164', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096173', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096191', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096200', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096209', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096218', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096227', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096182', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096038', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095966', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095930', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095912', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095903', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096236', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096083', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096002', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095957', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095939', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095921', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1695 | Q34 | What are the names of the genes that are targeted by the drug Relugolix in the treatment of metastatic prostate cancer? | In the context of metastatic prostate cancer, the drug Relugolix targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic prostate cancer%" OR LOWER(efo_term) LIKE "%metastatic prostate cancer%") AND (LOWER(drugName) LIKE "%relugolix%" OR LOWER(tradeNames_list) LIKE "%relugolix%" OR LOWER(syns_list) LIKE "%relugolix%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096984', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096952', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096944', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096968', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096976', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096960', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1784 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of metastasis? | In the context of metastasis, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastasis%" OR LOWER(efo_term) LIKE "%metastasis%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099717', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099826', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099827', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099881', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099936', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099937', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099991', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100046', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100047', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100101', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100102', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100157', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100211', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100212', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099992', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099772', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099662', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099607', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099606', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100156', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099882', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099771', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099716', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099661', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1624 | Q34 | What are the names of the genes that are targeted by the drug Argatroban in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Argatroban targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%argatroban%" OR LOWER(tradeNames_list) LIKE "%argatroban%" OR LOWER(syns_list) LIKE "%argatroban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1093396', 'drugName': 'Argatroban', 'tradeNames_list': "['Acova', 'Argatroban', 'Argatroban in dextroseArgatroban in sodium chloride']", 'syns_list': "['Argatroban', 'Argatroban anhydrous', 'Argatroban hydrateArgatroban monohydrate', 'Argipidine', 'DK-7419', 'GN-1600', 'GN1600MCI-9038', 'MD-805']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093402', 'drugName': 'Argatroban', 'tradeNames_list': "['Acova', 'Argatroban', 'Argatroban in dextroseArgatroban in sodium chloride']", 'syns_list': "['Argatroban', 'Argatroban anhydrous', 'Argatroban hydrateArgatroban monohydrate', 'Argipidine', 'DK-7419', 'GN-1600', 'GN1600MCI-9038', 'MD-805']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.521 | Q34 | What are the names of the genes that are targeted by the drug Bepotastine Besylate in the treatment of Pruritus? | In the context of Pruritus, the drug Bepotastine Besylate targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pruritus%" OR LOWER(efo_term) LIKE "%pruritus%") AND (LOWER(drugName) LIKE "%bepotastine besylate%" OR LOWER(tradeNames_list) LIKE "%bepotastine besylate%" OR LOWER(syns_list) LIKE "%bepotastine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455768', 'drugName': 'Bepotastine Besylate', 'tradeNames_list': "['Bepreve']", 'syns_list': "['BB', 'Bepotastine Besilate', 'Bepotastine benzenesulfonate saltBepotastine besilate', 'Bepotastine besylate', 'TAU-284', 'Talion']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455771', 'drugName': 'Bepotastine Besylate', 'tradeNames_list': "['Bepreve']", 'syns_list': "['BB', 'Bepotastine Besilate', 'Bepotastine benzenesulfonate saltBepotastine besilate', 'Bepotastine besylate', 'TAU-284', 'Talion']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1967 | Q34 | What are the names of the genes that are targeted by the drug Sotorasib in the treatment of neoplasm? | In the context of neoplasm, the drug Sotorasib targets the gene KRAS proto-oncogene, GTPase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%sotorasib%" OR LOWER(tradeNames_list) LIKE "%sotorasib%" OR LOWER(syns_list) LIKE "%sotorasib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193506', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_1193499', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_1193505', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_1193498', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_1193497', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_1193504', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_1193495', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_1193502', 'drugName': 'Sotorasib', 'tradeNames_list': "['Lumakras']", 'syns_list': "['AMG-510', 'AMG510', 'Kras g12c inhibitor 9Kras mutant-targeting amg 510', 'Sotorasib']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'KRAS', 'approvedName': 'KRAS proto-oncogene, GTPase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1076 | Q34 | What are the names of the genes that are targeted by the drug Testosterone Cypionate in the treatment of orchitis? | In the context of orchitis, the drug Testosterone Cypionate targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%orchitis%" OR LOWER(efo_term) LIKE "%orchitis%") AND (LOWER(drugName) LIKE "%testosterone cypionate%" OR LOWER(tradeNames_list) LIKE "%testosterone cypionate%" OR LOWER(syns_list) LIKE "%testosterone cypionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921014', 'drugName': 'Testosterone Cypionate', 'tradeNames_list': "['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'TestosteroneTestosterone cypionate']", 'syns_list': "['Depo-Testadiol', 'NSC-9157Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionateTestosterone cyclopentylpropionate', 'Testosterone cypionateTestosterone cypionate ciii']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.480 | Q34 | What are the names of the genes that are targeted by the drug Dextroamphetamine in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Dextroamphetamine targets the gene solute carrier family 6 member 2, solute carrier family 18 member A2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%dextroamphetamine%" OR LOWER(tradeNames_list) LIKE "%dextroamphetamine%" OR LOWER(syns_list) LIKE "%dextroamphetamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418424', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418463', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418476', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418489', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418515', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418528', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418541', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418567', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418580', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418593', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418606', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418632', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418645', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418658', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418671', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418684', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418697', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418710', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418723', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418736', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418749', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418775', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418788', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418801', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418814', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418827', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418853', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418866', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418879', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418892', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418905', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418918', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418931', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418944', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418957', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418970', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418983', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418996', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419009', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419022', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419035', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419048', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419061', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419074', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419087', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419100', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419113', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419126', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418762', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418554', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418450', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418398', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418372', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418359', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418840', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418619', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418502', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418437', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418411', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418385', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.159 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of Hypercalcemia? | In the context of Hypercalcemia, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypercalcemia%" OR LOWER(efo_term) LIKE "%hypercalcemia%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218665', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219289', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219497', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219705', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220121', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220329', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220537', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220745', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219081', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218249', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217833', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217625', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219913', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218873', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218457', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218041', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1253 | Q34 | What are the names of the genes that are targeted by the drug Armodafinil in the treatment of narcolepsy? | In the context of narcolepsy, the drug Armodafinil targets the gene solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%narcolepsy%" OR LOWER(efo_term) LIKE "%narcolepsy%") AND (LOWER(drugName) LIKE "%armodafinil%" OR LOWER(tradeNames_list) LIKE "%armodafinil%" OR LOWER(syns_list) LIKE "%armodafinil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939046', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939083', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939084', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939102', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939121', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939122', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939140', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939159', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939160', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939178', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939179', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939198', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939216', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939217', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939235', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939236', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939254', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939255', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939273', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939274', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939292', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939311', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939312', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939330', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939331', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939349', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939368', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939369', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939293', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939141', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939065', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939027', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939008', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939007', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939350', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939197', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939103', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939064', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939045', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939026', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1204 | Q34 | What are the names of the genes that are targeted by the drug Albuterol Sulfate in the treatment of asthma? | In the context of asthma, the drug Albuterol Sulfate targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%albuterol sulfate%" OR LOWER(tradeNames_list) LIKE "%albuterol sulfate%" OR LOWER(syns_list) LIKE "%albuterol sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936412', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936205', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936376', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936222', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936212', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936322', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936231', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936214', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936358', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936240', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936447', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936394', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936249', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936474', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936223', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936313', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936258', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936483', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936230', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936331', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936267', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936232', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936349', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936276', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936437', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936239', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936285', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936455', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936241', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936385', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936294', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936456', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936248', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936403', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936303', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936482', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936250', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936311', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936312', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936475', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936257', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936320', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936321', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936491', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936259', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936329', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936330', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936484', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936266', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936338', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936339', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936268', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936347', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936348', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936429', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936275', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936356', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936439', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936277', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936365', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936366', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936438', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936284', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936374', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936375', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936465', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936286', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936383', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936384', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936448', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936293', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936392', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936393', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936464', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936295', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936401', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936402', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936457', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936302', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936410', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936411', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936492', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936304', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936419', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936420', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936500', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936493', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936466', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936446', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936430', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936428', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936421', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936340', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936357', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936367', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936221', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936473', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936213', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936203', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936204', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma, Exercise-Induced', 'efo_term': 'asthma', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.17 | Q34 | What are the names of the genes that are targeted by the drug Cyclobenzaprine Hydrochloride in the treatment of spinal cord disease? | In the context of spinal cord disease, the drug Cyclobenzaprine Hydrochloride targets the gene 5-hydroxytryptamine receptor 2C and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spinal cord disease%" OR LOWER(efo_term) LIKE "%spinal cord disease%") AND (LOWER(drugName) LIKE "%cyclobenzaprine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cyclobenzaprine hydrochloride%" OR LOWER(syns_list) LIKE "%cyclobenzaprine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_151279', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151297', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151303', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151309', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151321', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151327', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151333', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151345', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151351', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151357', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151363', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151375', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151381', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151387', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151393', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151399', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151405', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151411', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151417', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151423', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151429', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151435', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151339', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151291', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151267', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151255', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151249', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151369', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151315', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151285', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151273', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151261', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1548 | Q34 | What are the names of the genes that are targeted by the drug Belumosudil Mesylate in the treatment of graft versus host disease? | In the context of graft versus host disease, the drug Belumosudil Mesylate targets the gene Rho associated coiled-coil containing protein kinase 2 and Rho associated coiled-coil containing protein kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%graft versus host disease%" OR LOWER(efo_term) LIKE "%graft versus host disease%") AND (LOWER(drugName) LIKE "%belumosudil mesylate%" OR LOWER(tradeNames_list) LIKE "%belumosudil mesylate%" OR LOWER(syns_list) LIKE "%belumosudil mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1076381', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076384', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076385', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076383', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076377', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076376', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076379', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076382', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076380', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076378', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'syns_list': "['Belumosudil mesylate', 'KD025 mesylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1079 | Q34 | What are the names of the genes that are targeted by the drug Enzalutamide in the treatment of cancer? | In the context of cancer, the drug Enzalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%enzalutamide%" OR LOWER(tradeNames_list) LIKE "%enzalutamide%" OR LOWER(syns_list) LIKE "%enzalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921123', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921351', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921275', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921085', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921033', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921332', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921204', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921105', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921318', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921333', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921237', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921067', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921048', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921219', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921261', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921356', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921180', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921086', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921029', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921199', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921200', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921052', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921028', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921124', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921071', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921314', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921142', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921256', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921143', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921090', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921294', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921104', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921299', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921276', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921162', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921257', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921295', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921313', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921185', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921181', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921242', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921128', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921147', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921109', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921161', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921337', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921218', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921066', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921223', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921280', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921166', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921047', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921238', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921352', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921312', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921350', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921179', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921160', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921103', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921027', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921198', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921065', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921217', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921122', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921084', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921293', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921236', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921255', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921046', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921331', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921141', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921274', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921080', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921137', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921251', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921252', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921138', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921081', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921156', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921271', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921290', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921157', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921308', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921289', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921309', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921042', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921061', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921099', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921270', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921175', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921327', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921328', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921176', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921100', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921194', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921062', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921195', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921118', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921213', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921214', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1952 | Q34 | What are the names of the genes that are targeted by the drug Baclofen in the treatment of Rigidity? | In the context of Rigidity, the drug Baclofen targets the gene gamma-aminobutyric acid type B receptor subunit 1 and gamma-aminobutyric acid type B receptor subunit 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rigidity%" OR LOWER(efo_term) LIKE "%rigidity%") AND (LOWER(drugName) LIKE "%baclofen%" OR LOWER(tradeNames_list) LIKE "%baclofen%" OR LOWER(syns_list) LIKE "%baclofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193244', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193319', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193344', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193294', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193144', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193119', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193194', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193269', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193219', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193169', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Rigidity', 'efo_term': 'Rigidity', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.550 | Q34 | What are the names of the genes that are targeted by the drug Levocetirizine Dihydrochloride in the treatment of urticaria? | In the context of urticaria, the drug Levocetirizine Dihydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urticaria%" OR LOWER(efo_term) LIKE "%urticaria%") AND (LOWER(drugName) LIKE "%levocetirizine dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%levocetirizine dihydrochloride%" OR LOWER(syns_list) LIKE "%levocetirizine dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455994', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_list': "['Levocetirizine dihydrochloride', 'Xusal', 'Xyzal', 'Xyzal allergy 24hrXyzall']", 'syns_list': "['Cetirizine (r)-form dihydrochloride', 'Cetirizine hydrochloride (r)-Levocetirizine dihydrochloride', 'Levocetirizine hydrochlorideLevocetirizine monohydrochloride', 'NSC-758898', 'UCB 28556', 'UCB-28556']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urticaria', 'efo_term': 'urticaria', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1552 | Q34 | What are the names of the genes that are targeted by the drug Vorinostat in the treatment of cancer? | In the context of cancer, the drug Vorinostat targets the gene histone deacetylase 1, histone deacetylase 3, histone deacetylase 6 and histone deacetylase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%vorinostat%" OR LOWER(tradeNames_list) LIKE "%vorinostat%" OR LOWER(syns_list) LIKE "%vorinostat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1078457', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079601', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079249', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079337', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077577', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076873', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078545', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077401', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077313', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078105', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077049', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078369', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077225', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077137', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078193', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077665', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077929', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076697', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076785', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078633', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077841', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078897', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077489', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1079073', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079425', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1078809', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078985', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078017', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078281', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078721', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077753', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1079513', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079777', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076961', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079161', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079689', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1078544', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1076872', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077400', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077488', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078808', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079336', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1078896', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079072', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079160', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079424', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079600', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077224', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079688', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077664', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076696', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076960', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078632', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079776', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1078720', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079248', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077576', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077752', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078456', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079512', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077136', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077048', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077840', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078984', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077928', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076784', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078016', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077312', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078104', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078280', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078192', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078368', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077565', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077639', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076772', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076945', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077297', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076773', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076947', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077653', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076948', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076949', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077299', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077740', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077727', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077737', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077739', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076671', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077287', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077741', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077825', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077023', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077815', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077033', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077827', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077829', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077035', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077036', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077828', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077037', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.663 | Q34 | What are the names of the genes that are targeted by the drug Regadenoson in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Regadenoson targets the gene adenosine A2a receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%regadenoson%" OR LOWER(tradeNames_list) LIKE "%regadenoson%" OR LOWER(syns_list) LIKE "%regadenoson%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695324', 'drugName': 'Regadenoson', 'tradeNames_list': "['Lexiscan']", 'syns_list': "['CVT-3146', 'Rapiscan', 'Regadenoson', 'Regadenoson hydrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADORA2A', 'approvedName': 'adenosine A2a receptor'}, {'UUID': 'DrugTargetsIndication121923_text_695325', 'drugName': 'Regadenoson', 'tradeNames_list': "['Lexiscan']", 'syns_list': "['CVT-3146', 'Rapiscan', 'Regadenoson', 'Regadenoson hydrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADORA2A', 'approvedName': 'adenosine A2a receptor'}, {'UUID': 'DrugTargetsIndication121923_text_695326', 'drugName': 'Regadenoson', 'tradeNames_list': "['Lexiscan']", 'syns_list': "['CVT-3146', 'Rapiscan', 'Regadenoson', 'Regadenoson hydrate']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ADORA2A', 'approvedName': 'adenosine A2a receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1796 | Q34 | What are the names of the genes that are targeted by the drug Nizatidine in the treatment of gastroesophageal reflux disease? | In the context of gastroesophageal reflux disease, the drug Nizatidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastroesophageal reflux disease%" OR LOWER(efo_term) LIKE "%gastroesophageal reflux disease%") AND (LOWER(drugName) LIKE "%nizatidine%" OR LOWER(tradeNames_list) LIKE "%nizatidine%" OR LOWER(syns_list) LIKE "%nizatidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100310', 'drugName': 'Nizatidine', 'tradeNames_list': "['Axid', 'Axid ar', 'Nizatidine', 'Zinga 150', 'Zinga 300']", 'syns_list': "['Acinon', 'LY 139037', 'LY-139037', 'NSC-759289', 'Nizatidine']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1026 | Q34 | What are the names of the genes that are targeted by the drug Copanlisib Hydrochloride in the treatment of neoplasm of mature B-cells? | In the context of neoplasm of mature B-cells, the drug Copanlisib Hydrochloride targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm of mature b-cells%" OR LOWER(efo_term) LIKE "%neoplasm of mature b-cells%") AND (LOWER(drugName) LIKE "%copanlisib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%copanlisib hydrochloride%" OR LOWER(syns_list) LIKE "%copanlisib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858360', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'syns_list': "['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_858378', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'syns_list': "['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_858342', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'syns_list': "['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858324', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'syns_list': "['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858315', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'syns_list': "['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858369', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'syns_list': "['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_858351', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'syns_list': "['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_858333', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': "['Aliqopa']", 'syns_list': "['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1660 | Q34 | What are the names of the genes that are targeted by the drug Spironolactone in the treatment of hypertension? | In the context of hypertension, the drug Spironolactone targets the gene nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%spironolactone%" OR LOWER(tradeNames_list) LIKE "%spironolactone%" OR LOWER(syns_list) LIKE "%spironolactone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094464', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094540', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094616', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094350', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094388', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094578', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094426', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094502', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094654', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094384', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094460', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094612', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094574', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094498', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094346', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094536', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094422', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094650', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094368', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094520', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094558', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094330', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094444', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094596', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094406', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094482', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094634', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1517 | Q34 | What are the names of the genes that are targeted by the drug Azilsartan Medoxomil in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Azilsartan Medoxomil targets the gene angiotensin II receptor type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%azilsartan medoxomil%" OR LOWER(tradeNames_list) LIKE "%azilsartan medoxomil%" OR LOWER(syns_list) LIKE "%azilsartan medoxomil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072694', 'drugName': 'Azilsartan Medoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['AR-14', 'Azilsartan medoxomil', 'Ipreziv', 'TAK 491', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072682', 'drugName': 'Azilsartan Medoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['AR-14', 'Azilsartan medoxomil', 'Ipreziv', 'TAK 491', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072679', 'drugName': 'Azilsartan Medoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['AR-14', 'Azilsartan medoxomil', 'Ipreziv', 'TAK 491', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072688', 'drugName': 'Azilsartan Medoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['AR-14', 'Azilsartan medoxomil', 'Ipreziv', 'TAK 491', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072691', 'drugName': 'Azilsartan Medoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['AR-14', 'Azilsartan medoxomil', 'Ipreziv', 'TAK 491', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072685', 'drugName': 'Azilsartan Medoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['AR-14', 'Azilsartan medoxomil', 'Ipreziv', 'TAK 491', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.966 | Q34 | What are the names of the genes that are targeted by the drug Ruxolitinib Phosphate in the treatment of Myelofibrosis? | In the context of Myelofibrosis, the drug Ruxolitinib Phosphate targets the gene Janus kinase 1 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myelofibrosis%" OR LOWER(efo_term) LIKE "%myelofibrosis%") AND (LOWER(drugName) LIKE "%ruxolitinib phosphate%" OR LOWER(tradeNames_list) LIKE "%ruxolitinib phosphate%" OR LOWER(syns_list) LIKE "%ruxolitinib phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_843654', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843678', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843680', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843691', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843704', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843706', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843717', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843730', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843732', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843743', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843745', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843758', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843769', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843771', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843782', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843784', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843795', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843797', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843808', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843810', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843821', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843834', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843836', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843847', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843849', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843860', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843873', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843875', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843886', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843888', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843899', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843901', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843912', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843914', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843925', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843927', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843938', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843940', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843951', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843953', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843964', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843966', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843977', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843979', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843990', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843992', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844003', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844005', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844016', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844018', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844029', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844042', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844044', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844055', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844057', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844068', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844070', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844083', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844094', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844096', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844107', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844109', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844120', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844122', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844133', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844135', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844146', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844148', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844159', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844161', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844172', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844174', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844185', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844187', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844198', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844200', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844211', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844213', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844224', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844226', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844237', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844239', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844250', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844252', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844263', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844265', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844031', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843823', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843719', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843667', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843641', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843628', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843626', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_844081', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843862', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843756', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843693', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843665', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843652', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843639', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'syns_list': "['INCB-018424 PHOSPHATE', 'INCB-018424 SALT', 'INCB-18424 PHOSPHATEINCB018424 PHOSPHATE', 'INCB018424 SALT', 'OpzeluraRuxolitinib (as phosphate)', 'Ruxolitinib monophosphateRuxolitinib phosphate']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1864 | Q34 | What are the names of the genes that are targeted by the drug Obeticholic Acid in the treatment of biliary liver cirrhosis? | In the context of biliary liver cirrhosis, the drug Obeticholic Acid targets the gene nuclear receptor subfamily 1 group H member 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%biliary liver cirrhosis%" OR LOWER(efo_term) LIKE "%biliary liver cirrhosis%") AND (LOWER(drugName) LIKE "%obeticholic acid%" OR LOWER(tradeNames_list) LIKE "%obeticholic acid%" OR LOWER(syns_list) LIKE "%obeticholic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104397', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104442', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104457', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104472', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104502', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104517', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104532', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104562', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104577', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104592', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104607', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104427', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104367', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104337', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104322', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104547', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104487', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104412', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104382', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1104352', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'syns_list': "['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q35.589 | Q35 | Is the SNP rs204905 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs204905 has a p-value of 1.34e-13 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs204905'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19974857', 'SNP': 'rs204905', 'p': 1.335e-13, 'b': 0.0647}] | general | Select, Order By | GWAS Significance |
Q35.1868 | Q35 | Is the SNP rs746614453 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs746614453 has a p-value of 7.54e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs746614453'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_15496017', 'SNP': 'rs746614453', 'p': 0.7545, 'b': -0.0773}] | general | Select, Order By | GWAS Significance |
Q35.1061 | Q35 | Is the SNP rs543196347 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs543196347 has a p-value of 7.77e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs543196347'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_16857600', 'SNP': 'rs543196347', 'p': 0.7774, 'b': -0.0451}] | general | Select, Order By | GWAS Significance |
Q35.1084 | Q35 | Is the SNP rs909740053 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs909740053 has a p-value of 4.69e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs909740053'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5351785', 'SNP': 'rs909740053', 'p': 0.469, 'b': -0.2242}] | general | Select, Order By | GWAS Significance |
Q35.925 | Q35 | Is the SNP rs35114168 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs35114168 has a p-value of 6.26e-36 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs35114168'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_2642960', 'SNP': 'rs35114168', 'p': 6.257000000000001e-36, 'b': 0.107}] | general | Select, Order By | GWAS Significance |
Q35.73 | Q35 | Is the SNP rs145129423 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs145129423 has a p-value of 1.85e-10 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs145129423'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_3417957', 'SNP': 'rs145129423', 'p': 1.85e-10, 'b': -0.0525}] | general | Select, Order By | GWAS Significance |
Q35.435 | Q35 | Is the SNP rs41290108 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs41290108 has a p-value of 3.52e-10 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs41290108'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19974236', 'SNP': 'rs41290108', 'p': 3.521e-10, 'b': -0.1626}] | general | Select, Order By | GWAS Significance |
Q35.911 | Q35 | Is the SNP rs10129711 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs10129711 has a p-value of 3.24e-11 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs10129711'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_17074425', 'SNP': 'rs10129711', 'p': 3.244e-11, 'b': 0.0634}] | general | Select, Order By | GWAS Significance |
Q35.922 | Q35 | Is the SNP rs6933231 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs6933231 has a p-value of 1.06e-09 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs6933231'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_8300717', 'SNP': 'rs6933231', 'p': 1.059e-09, 'b': -0.0517}] | general | Select, Order By | GWAS Significance |
Q35.1679 | Q35 | Is the SNP rs78985149 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs78985149 has a p-value of 8.85e-02 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs78985149'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19808421', 'SNP': 'rs78985149', 'p': 0.0885, 'b': 0.0368}] | general | Select, Order By | GWAS Significance |
Q35.1272 | Q35 | Is the SNP rs150431838 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs150431838 has a p-value of 4.34e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs150431838'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_332499', 'SNP': 'rs150431838', 'p': 0.4339, 'b': -0.089}] | general | Select, Order By | GWAS Significance |
Q35.1094 | Q35 | Is the SNP rs188766537 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs188766537 has a p-value of 1.09e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs188766537'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_9250310', 'SNP': 'rs188766537', 'p': 0.1094, 'b': -0.1243}] | general | Select, Order By | GWAS Significance |
Q35.389 | Q35 | Is the SNP rs62621252 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs62621252 has a p-value of 4.58e-08 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs62621252'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18744159', 'SNP': 'rs62621252', 'p': 4.58e-08, 'b': -0.0533}] | general | Select, Order By | GWAS Significance |
Q35.841 | Q35 | Is the SNP rs6977955 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs6977955 has a p-value of 2.42e-08 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs6977955'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_9568611', 'SNP': 'rs6977955', 'p': 2.421e-08, 'b': -0.0558}] | general | Select, Order By | GWAS Significance |
Q35.774 | Q35 | Is the SNP rs55840414 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs55840414 has a p-value of 2.13e-13 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs55840414'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19973937', 'SNP': 'rs55840414', 'p': 2.132e-13, 'b': -0.1014}] | general | Select, Order By | GWAS Significance |
Q35.1805 | Q35 | Is the SNP rs7269619 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs7269619 has a p-value of 5.45e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs7269619'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20241836', 'SNP': 'rs7269619', 'p': 0.5455, 'b': 0.0051}] | general | Select, Order By | GWAS Significance |
Q35.1992 | Q35 | Is the SNP rs557907275 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs557907275 has a p-value of 8.92e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs557907275'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_17793497', 'SNP': 'rs557907275', 'p': 0.8917, 'b': -0.0137}] | general | Select, Order By | GWAS Significance |
Q35.1066 | Q35 | Is the SNP rs145813884 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs145813884 has a p-value of 3.90e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs145813884'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_15266038', 'SNP': 'rs145813884', 'p': 0.39, 'b': -0.0432}] | general | Select, Order By | GWAS Significance |
Q35.58 | Q35 | Is the SNP rs583162 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs583162 has a p-value of 8.93e-16 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs583162'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_14336976', 'SNP': 'rs583162', 'p': 8.928e-16, 'b': 0.0658}] | general | Select, Order By | GWAS Significance |
Q35.1688 | Q35 | Is the SNP rs570340486 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs570340486 has a p-value of 7.08e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs570340486'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_2260076', 'SNP': 'rs570340486', 'p': 0.7083, 'b': 0.1363}] | general | Select, Order By | GWAS Significance |
Q35.1955 | Q35 | Is the SNP rs62410505 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs62410505 has a p-value of 7.64e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs62410505'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5020282', 'SNP': 'rs62410505', 'p': 0.7636, 'b': -0.0061}] | general | Select, Order By | GWAS Significance |
Q35.1218 | Q35 | Is the SNP rs111760960 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs111760960 has a p-value of 3.33e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs111760960'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_4485684', 'SNP': 'rs111760960', 'p': 0.3334, 'b': -0.0197}] | general | Select, Order By | GWAS Significance |
Q35.1680 | Q35 | Is the SNP rs7212238 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs7212238 has a p-value of 2.45e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs7212238'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18855330', 'SNP': 'rs7212238', 'p': 0.245, 'b': 0.0249}] | general | Select, Order By | GWAS Significance |
Q35.1975 | Q35 | Is the SNP rs139146569 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs139146569 has a p-value of 1.33e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs139146569'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_14685733', 'SNP': 'rs139146569', 'p': 0.1328, 'b': 0.0429}] | general | Select, Order By | GWAS Significance |
Q35.213 | Q35 | Is the SNP rs2171086 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs2171086 has a p-value of 1.87e-11 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs2171086'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_8348778', 'SNP': 'rs2171086', 'p': 1.866e-11, 'b': 0.0614}] | general | Select, Order By | GWAS Significance |
Q35.1534 | Q35 | Is the SNP rs186122488 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs186122488 has a p-value of 1.92e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs186122488'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_11179017', 'SNP': 'rs186122488', 'p': 0.1921, 'b': 0.26}] | general | Select, Order By | GWAS Significance |
Q35.1135 | Q35 | Is the SNP rs1026503432 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs1026503432 has a p-value of 9.38e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs1026503432'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_10597943', 'SNP': 'rs1026503432', 'p': 0.9381, 'b': -0.0183}] | general | Select, Order By | GWAS Significance |
Q35.131 | Q35 | Is the SNP rs4936635 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs4936635 has a p-value of 4.08e-08 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs4936635'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_14615302', 'SNP': 'rs4936635', 'p': 4.084e-08, 'b': 0.1042}] | general | Select, Order By | GWAS Significance |
Q35.819 | Q35 | Is the SNP rs151057105 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs151057105 has a p-value of 5.50e-09 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs151057105'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_9787764', 'SNP': 'rs151057105', 'p': 5.501e-09, 'b': -0.0816}] | general | Select, Order By | GWAS Significance |
Q35.1282 | Q35 | Is the SNP rs183054305 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs183054305 has a p-value of 8.76e-02 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs183054305'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_17360853', 'SNP': 'rs183054305', 'p': 0.08757, 'b': 0.1182}] | general | Select, Order By | GWAS Significance |
Q35.1872 | Q35 | Is the SNP rs1796361 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs1796361 has a p-value of 5.15e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs1796361'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_15050522', 'SNP': 'rs1796361', 'p': 0.5154, 'b': 0.0061}] | general | Select, Order By | GWAS Significance |
Q35.438 | Q35 | Is the SNP rs72846701 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs72846701 has a p-value of 4.07e-19 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs72846701'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_2642890', 'SNP': 'rs72846701', 'p': 4.075e-19, 'b': 0.0932}] | general | Select, Order By | GWAS Significance |
Q35.417 | Q35 | Is the SNP rs2532265 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs2532265 has a p-value of 2.82e-08 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs2532265'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18747056', 'SNP': 'rs2532265', 'p': 2.818e-08, 'b': -0.0549}] | general | Select, Order By | GWAS Significance |
Q35.1504 | Q35 | Is the SNP rs573977605 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs573977605 has a p-value of 2.92e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs573977605'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_15652992', 'SNP': 'rs573977605', 'p': 0.2916, 'b': -0.205}] | general | Select, Order By | GWAS Significance |
Q35.234 | Q35 | Is the SNP rs2276579 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs2276579 has a p-value of 3.36e-10 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs2276579'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_2642642', 'SNP': 'rs2276579', 'p': 3.364e-10, 'b': 0.0633}] | general | Select, Order By | GWAS Significance |
Q35.1708 | Q35 | Is the SNP rs61974215 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs61974215 has a p-value of 1.16e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs61974215'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_16379638', 'SNP': 'rs61974215', 'p': 0.1159, 'b': 0.0313}] | general | Select, Order By | GWAS Significance |
Q35.895 | Q35 | Is the SNP rs556056228 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs556056228 has a p-value of 5.10e-13 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs556056228'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19974947', 'SNP': 'rs556056228', 'p': 5.099e-13, 'b': 0.8295}] | general | Select, Order By | GWAS Significance |
Q35.1625 | Q35 | Is the SNP rs746949160 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs746949160 has a p-value of 3.64e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs746949160'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_11955530', 'SNP': 'rs746949160', 'p': 0.3641, 'b': -0.3645}] | general | Select, Order By | GWAS Significance |
Q35.699 | Q35 | Is the SNP rs11623019 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs11623019 has a p-value of 1.94e-12 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs11623019'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_17074487', 'SNP': 'rs11623019', 'p': 1.935e-12, 'b': 0.0693}] | general | Select, Order By | GWAS Significance |
Q35.1769 | Q35 | Is the SNP rs79573082 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs79573082 has a p-value of 1.75e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs79573082'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_10761213', 'SNP': 'rs79573082', 'p': 0.175, 'b': -0.019}] | general | Select, Order By | GWAS Significance |
Q35.301 | Q35 | Is the SNP rs469420 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs469420 has a p-value of 3.02e-09 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs469420'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20682095', 'SNP': 'rs469420', 'p': 3.018e-09, 'b': -0.0486}] | general | Select, Order By | GWAS Significance |
Q35.1399 | Q35 | Is the SNP rs17436486 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs17436486 has a p-value of 5.00e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs17436486'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_13777221', 'SNP': 'rs17436486', 'p': 0.5005, 'b': 0.0059}] | general | Select, Order By | GWAS Significance |
Q35.1987 | Q35 | Is the SNP rs150645611 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs150645611 has a p-value of 7.21e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs150645611'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18644748', 'SNP': 'rs150645611', 'p': 0.7211, 'b': 0.0533}] | general | Select, Order By | GWAS Significance |
Q35.102 | Q35 | Is the SNP rs7502672 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs7502672 has a p-value of 1.72e-09 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs7502672'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18862884', 'SNP': 'rs7502672', 'p': 1.717e-09, 'b': 0.0493}] | general | Select, Order By | GWAS Significance |
Q35.831 | Q35 | Is the SNP rs10445336 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs10445336 has a p-value of 3.57e-08 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs10445336'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18744307', 'SNP': 'rs10445336', 'p': 3.574e-08, 'b': -0.0538}] | general | Select, Order By | GWAS Significance |
Q35.359 | Q35 | Is the SNP rs17186848 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs17186848 has a p-value of 3.49e-15 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs17186848'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_1353308', 'SNP': 'rs17186848', 'p': 3.489e-15, 'b': 0.0652}] | general | Select, Order By | GWAS Significance |
Q35.114 | Q35 | Is the SNP rs56845483 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs56845483 has a p-value of 1.38e-12 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs56845483'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19976849', 'SNP': 'rs56845483', 'p': 1.383e-12, 'b': 0.2283}] | general | Select, Order By | GWAS Significance |
Q35.1440 | Q35 | Is the SNP rs17428878 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs17428878 has a p-value of 8.82e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs17428878'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5189798', 'SNP': 'rs17428878', 'p': 0.8817, 'b': -0.0035}] | general | Select, Order By | GWAS Significance |
Q35.1840 | Q35 | Is the SNP rs1516962 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs1516962 has a p-value of 8.43e-03 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs1516962'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_11559718', 'SNP': 'rs1516962', 'p': 0.008435, 'b': 0.0661}] | general | Select, Order By | GWAS Significance |
Q35.952 | Q35 | Is the SNP rs62063265 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs62063265 has a p-value of 3.64e-08 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs62063265'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18745301', 'SNP': 'rs62063265', 'p': 3.636e-08, 'b': -0.0539}] | general | Select, Order By | GWAS Significance |
Q35.1186 | Q35 | Is the SNP rs183842958 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs183842958 has a p-value of 4.88e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs183842958'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_7257023', 'SNP': 'rs183842958', 'p': 0.4881, 'b': -0.0605}] | general | Select, Order By | GWAS Significance |
Q35.456 | Q35 | Is the SNP rs56166491 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs56166491 has a p-value of 2.36e-08 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs56166491'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18745387', 'SNP': 'rs56166491', 'p': 2.356e-08, 'b': -0.0547}] | general | Select, Order By | GWAS Significance |
Q35.876 | Q35 | Is the SNP rs183610051 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs183610051 has a p-value of 2.09e-59 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs183610051'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19974065', 'SNP': 'rs183610051', 'p': 2.094e-59, 'b': 0.6545}] | general | Select, Order By | GWAS Significance |
Q35.1545 | Q35 | Is the SNP rs115572681 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs115572681 has a p-value of 4.09e-01 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs115572681'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18967515', 'SNP': 'rs115572681', 'p': 0.4092, 'b': -0.0146}] | general | Select, Order By | GWAS Significance |
Q35.1701 | Q35 | Is the SNP rs778920473 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs778920473 has a p-value of 7.60e-02 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs778920473'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_1241563', 'SNP': 'rs778920473', 'p': 0.07596, 'b': -0.5865}] | general | Select, Order By | GWAS Significance |
Q35.1436 | Q35 | Is the SNP rs7071891 significant in AD? | No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs7071891 has a p-value of 3.94e-02 and therefore is not significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs7071891'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_13232675', 'SNP': 'rs7071891', 'p': 0.03935, 'b': 0.0296}] | general | Select, Order By | GWAS Significance |
Q35.915 | Q35 | Is the SNP rs603615 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs603615 has a p-value of 4.24e-19 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs603615'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_14336196', 'SNP': 'rs603615', 'p': 4.245e-19, 'b': -0.0916}] | general | Select, Order By | GWAS Significance |
Q35.310 | Q35 | Is the SNP rs28607628 significant in AD? | Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs28607628 has a p-value of 3.79e-13 and therefore is significant in AD. | SELECT UUID, SNP, p, b
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs28607628'
ORDER BY p
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19976954', 'SNP': 'rs28607628', 'p': 3.787e-13, 'b': 0.1239}] | general | Select, Order By | GWAS Significance |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.